CompletedPHASE1, PHASE2NCT01035463

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

Studying ALK-negative anaplastic large cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Nebraska
Principal Investigator
Julie Vose, MD, MBA, OTR/L
University of Nebraska
Intervention
Autologous Hematopoietic Stem Cell Transplantation(procedure)
Enrollment
74 enrolled
Eligibility
19 years · All sexes
Timeline
20092018

Study locations (3)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01035463 on ClinicalTrials.gov

Other trials for ALK-negative anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for ALK-negative anaplastic large cell lymphoma

← Back to all trials